Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

• Talha Badar,
• Ahmad Nanaa,
• Ehab Atallah,
• Rory M. Shallis,
• Sacchi de Camargo Correia Guilherme,
• Aaron D. Goldberg,
• Antoine N. Saliba,
• Anand Patel,
• Jan P. Bewersdorf,
• Adam S. DuVall,
• Danielle Bradshaw,
• Yasmin Abaza,
• Guru Subramanian Guru Murthy,
• Neil Palmisiano,
• Amer M. Zeidan,
• Vamsi Kota,
• Mark R. Litzow

Affiliations

Talha Badar

Division of Hematology-Oncology, Mayo Clinic

Ahmad Nanaa

Division of Hematology-Oncology, Mayo Clinic

Ehab Atallah

Division of Hematology and Medical Oncology, Medical College of Wisconsin

Rory M. Shallis

Section of Hematology, Department of Internal Medicine, Yale School of Medicine

Sacchi de Camargo Correia Guilherme

Department of Internal Medicine, Mount Sinai Health System

Aaron D. Goldberg

Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center

Antoine N. Saliba

Division of Hematology, Mayo Clinic

Anand Patel

Section of Hematology and Oncology, Department of Medicine, University of Chicago

Jan P. Bewersdorf

Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center

Adam S. DuVall

Division of Hematology and Oncology, Georgia Cancer Center

Danielle Bradshaw

Division of Hematology and Oncology, Georgia Cancer Center

Yasmin Abaza

Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital

Guru Subramanian Guru Murthy

Division of Hematology and Medical Oncology, Medical College of Wisconsin

Neil Palmisiano

Division of Hematology and Oncology, Jefferson University Hospital

Amer M. Zeidan

Section of Hematology, Department of Internal Medicine, Yale School of Medicine

Vamsi Kota

Division of Hematology and Oncology, Georgia Cancer Center

Mark R. Litzow

Division of Hematology, Mayo Clinic